Taprenepag

Drug Profile

Taprenepag

Alternative Names: PF 4217329; PF-04217329; Taprenepag isopropyl

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiglaucomas
  • Mechanism of Action Prostaglandin E EP2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 11 Aug 2011 Discontinued - Phase-II for Glaucoma in USA (Topical)
  • 30 Aug 2010 Phase-II development is ongoing in USA
  • 11 Mar 2008 Phase-II clinical trials in Glaucoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top